speb/financial-data huggingface dataset:
Financial scorecard for CAN.V (Basic Materials — Gold, Canada)
Report date: 2025-12-31 (annual)
Stock price: 0.03546099290780142
Market cap: 3017788 (USD: 2202764.9635036495)
P/B ratio: 1.9653908683848085
Debt to equity: 0.049699999999999994
Current ratio: 0.97
Interest coverage ratio: -174.4737851662404
Return on net tangible assets (%): -76.90251269761323
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: -0.48961727056365023 (Distress Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -1.6552852619203202
Total shareholder yield (%): -1.6552852619203202 (Minimal or Negative)
Momentum (%): 1m -37.056737588652474, 3m -59.515366430260045, 6m -79.60992907801419, 12m -75.88652482269504, composite -66.93847878444821 (Strong Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: 0.5366265820246363
FCF conversion rate: 5.10527749364351
Beneish M-score: -2.822829383807468 (Likely Safe)
ROE (%): -19.161939206414015
Asset turnover: 0
Equity multiplier (leverage): 1.4659183945353857
ROE archetype: Low Return
Treasury beta 1y: 0.001202135657490137 (R-squared: 2.0878133480214395e-05)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -30.687120840785038 (pretax: -38.84445676048739)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 20.679886685552407, ROIC 42.77620396600567, revenue growth 1y , 6m momentum 81.58640226628894
Sector percentiles: P/E , 6m momentum 83.06496390893948
Industry median P/E: 8.322060300477567; industry median ROIC: -7.9824265928961236
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.10245520320594022
Base cash flow: -2820782.4817518247
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CELC (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 85.1
Market cap: 4029070848 (USD: 4029070848)
P/B ratio: 103.99223002933209
Debt to equity: 6.0428
Current ratio: 12.31
Interest coverage ratio: -8.300246507806081
Return on net tangible assets (%): -99.09948622139187
Buffett classification: The Gruesome
Analyst consensus upside (%): 43.20133169791483
Rule of 40 score: 0
Altman Z-score: 5.758700850240709 (Safe Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.038122933498736036
Total shareholder yield (%): -0.038122933498736036 (Minimal or Negative)
Momentum (%): 1m -11.70367296119527, 3m -29.68685449888458, 6m -22.671512948659704, 12m 505.6939501779359, composite 177.87342674642946 (Strong Uptrend)
Lynch category: Turnaround (confidence: Medium)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: 0.0057235931116134875
FCF conversion rate: 1.0474820688480535
Beneish M-score: -2.0525396126998805 (Likely Safe)
ROE (%): -68.58904465212876
Asset turnover: 0
Equity multiplier (leverage): 5.690044132917965
ROE archetype: Low Return
Treasury beta 1y: 0.005120089410031526 (R-squared: 0.00014809329704879015)
Insider 90-day net shares: -3134000 (net value USD: -322531181.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 66.60649819494586, ROIC , revenue growth 1y , 6m momentum 46.02888086642599
Sector percentiles: P/E , 6m momentum 52.47134670487106
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.05485477990272206
Base cash flow: -177124000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CGON (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 69.32
Market cap: 6114195456 (USD: 6114195456)
P/B ratio: 5.467721372768665
Debt to equity: 0.0069
Current ratio: 31.3
Return on net tangible assets (%): -5.519824742210816
Buffett classification: The Gruesome
Analyst consensus upside (%): 33.99822695035459
Rule of 40 score: -5937.1080189253225
Altman Z-score: 84.76085042626315 (Safe Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.009060881419097375
Total shareholder yield (%): -0.009060881419097375 (Minimal or Negative)
Momentum (%): 1m 0.8731082654249045, 3m 0.9318578916715001, 6m 28.82363872886079, 12m 165.18745218056614, composite 64.21587199261303 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 8, recommendation: Short
Revenue growth 1y (%): 1982.6923076923076
Revenue deceleration: no
Accrual ratio: -0.003067175821312876
FCF conversion rate: 0.9509152519849838
Beneish M-score: -0.9696272437546304 (Strong Manipulation Signal)
ROE (%): -6.528152263550751
Net margin (%): -5558.818097876269
Asset turnover: 0.0011241121538009627
Equity multiplier (leverage): 1.0447158152247285
ROE archetype: Low Return
Treasury beta 1y: -0.0038570864470801203 (R-squared: 0.0008573002526219378)
Insider 90-day net shares: 317356 (net value USD: 20940511.00)
ROIC (%): -862.7860087016259 (pretax: -1092.1341882299062)
Incremental ROIC 3y (%): -619.664716562437 (pretax: -784.3857171676417)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 48.194945848375454, ROIC 40.794223826714806, revenue growth 1y 0.18050541516245489, 6m momentum 12.545126353790614
Sector percentiles: P/E , 6m momentum 10.92406876790831
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.05898823387278674
Base cash flow: -159684000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CGR.AX (Basic Materials — Other Industrial Metals & Mining, Australia)
Report date: 2025-06-30 (annual)
Stock price: 0.0625
Market cap: 10250414 (USD: 6699616.993464052)
Debt to equity: 0.0043
Current ratio: 42.14
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 81.25, 3m 24.999999999999975, 6m -8.750000000000014, 12m 34.82142857142857, composite -3.1219211822660236 (Strong Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.48 (Likely Safe)
ROE archetype: Standard Business
Treasury beta 1y: 0.0027500708746893304 (R-squared: 5.906152118265715e-05)
Insider 90-day net shares: 70000 (net value USD: 3990.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y , 6m momentum 25.97835137385512
Sector percentiles: P/E , 6m momentum 33.9811215991116
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.09090000000000001
Base cash flow: 0
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CGTX (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 0.92
Market cap: 82293424 (USD: 82293424)
P/B ratio: 2.274029333689947
Debt to equity: 0.015600000000000001
Current ratio: 5.92
Interest coverage ratio: -967.6
Return on net tangible assets (%): -15.051318912774564
Buffett classification: The Gruesome
Analyst consensus upside (%): 360.5263157894737
Rule of 40 score: 0
Altman Z-score: 0.6009588210454657 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.21022335879474405
Total shareholder yield (%): 0.21022335879474405 (Low Return)
Momentum (%): 1m -9.803921568627448, 3m -28.125, 6m -35.66433566433566, 12m 6.976744186046519, composite -15.061561500514989 (Moderate Uptrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: 0.022997752277298
FCF conversion rate: 1.212691466083151
Beneish M-score: -2.281659243241945 (Likely Safe)
ROE (%): -14.240752859057057
Asset turnover: 0
Equity multiplier (leverage): 1.3170359290766882
ROE archetype: Low Return
Treasury beta 1y: 0.003506258369443604 (R-squared: 0.0001378521112888065)
Insider 90-day net shares: 29175 (net value USD: 32492.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 26.805054151624546, ROIC , revenue growth 1y , 6m momentum 56.768953068592054
Sector percentiles: P/E , 6m momentum 62.428366762177646
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.1424826240221238
Base cash flow: -23268000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CNT.TO (Consumer Defensive — Food Distribution, Hong Kong)
Report date: 2026-03-31 (annual)
Stock price: 0.03546099290780142
Market cap: 5319247 (USD: 678475.3826530612)
P/B ratio: 1.5192039620828608
Debt to equity: 0.0101
Current ratio: 2.75
Interest coverage ratio: -99.19232202758107
Return on net tangible assets (%): -5.878537551932751
Buffett classification: The Gruesome
Rule of 40 score: -10.952062444771737
Altman Z-score: -5.352132052013762 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.498329372182728
Total shareholder yield (%): 0.498329372182728 (Low Return)
Momentum (%): 1m 25.88652482269504, 3m 21.453900709219873, 6m -2.1276595744681, 12m -31.10435663627153, composite -8.648462881306754 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 10, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): 2.8695586825584485
Revenue CAGR 3y (%): 7.039496373694898
Revenue deceleration: yes
Revenue growth consistency score: 11.911123963668153
Accrual ratio: -0.00791901728231729
FCF conversion rate: 0.26568171085475273
Beneish M-score: -2.573754007420355 (Likely Safe)
ROE (%): -3.9097950775138544
Net margin (%): -5.07189587605339
Asset turnover: 0.6553408525005514
Equity multiplier (leverage): 1.176295470365722
ROE archetype: Low Return
Treasury beta 1y: -0.0037790807607895154 (R-squared: 6.532892989243147e-05)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -4.106269090204559 (pretax: -5.19780897494248)
Incremental ROIC 3y (%): 38.956297078994766 (pretax: 49.31176845442375)
Capital allocation category: Turnaround Compounder
Industry percentiles: P/E , P/B 33.80281690140845, ROIC 73.23943661971832, revenue growth 1y 21.12676056338028, 6m momentum 36.61971830985916
Sector percentiles: P/E , 6m momentum 34.178131788559014
Industry median P/E: 0.7382173578452391; industry median ROIC: 6.126309823527797
Sector median P/E: 1.0302878025850322; sector median ROIC: 7.163828537874342
WACC: 0.05
Base cash flow: -123798.21428571429
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CNTB (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 2.14
Market cap: 134742656 (USD: 134742656)
P/B ratio: 3.8703351444056024
Debt to equity: 0.0163
Current ratio: 3.23
Return on net tangible assets (%): -45.17144199154532
Buffett classification: The Gruesome
Analyst consensus upside (%): 172.13740458015266
Rule of 40 score: -111052.29863540712
Altman Z-score: -5.478094680283838 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.002226466427973633
Total shareholder yield (%): -0.002226466427973633 (Minimal or Negative)
Momentum (%): 1m 0.9433962264150951, 3m -15.079365079365076, 6m -15.748031496062989, 12m -8.936170212765955, composite -13.538210205993751 (Moderate Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 10, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: -0.05842897856915301
FCF conversion rate: 0.8250850603154964
Beneish M-score: -2.8305345503563037 (Likely Safe)
ROE (%): -45.856529910286866
Net margin (%): -125214.6296750539
Asset turnover: 0.00026677572950120973
Equity multiplier (leverage): 1.372776379088212
ROE archetype: Low Return
Treasury beta 1y: -0.00266799831953021 (R-squared: 0.00013472464217688114)
Insider 90-day net shares: 150000 (net value USD: 371610.00)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E , P/B 40.25270758122744, ROIC , revenue growth 1y , 6m momentum 39.16967509025271
Sector percentiles: P/E , 6m momentum 45.45128939828081
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.10171013084258357
Base cash flow: -55208000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CNTY (Consumer Cyclical — Resorts & Casinos, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 1.17
Market cap: 32916238 (USD: 32916238)
Debt to equity: -44.27806363973161
Current ratio: 1.22
Interest coverage ratio: 0.45334720776968435
Buffett classification: The Great
Analyst consensus upside (%): 107.19424460431655
Rule of 40 score: -3.5360953356252143
Altman Z-score: -0.08476365820241033 (Distress Zone)
Piotroski F-score: 5 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 1.248623855496488
Debt paydown yield (%): 18.56226704886506
Total shareholder yield (%): 19.810890904361546 (High Return)
Momentum (%): 1m -9.302325581395356, 3m -18.181818181818183, 6m -26.87500000000001, 12m -54.11764705882353, composite -31.48952762923351 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 1, short score 7, recommendation: Neutral
Revenue growth 1y (%): 5.2099384405449145
Revenue deceleration: no
Accrual ratio: -0.009550214835782998
FCF conversion rate: 0.2667748917748918
Beneish M-score: -2.442225862623246 (Likely Safe)
Net margin (%): -10.772448065054393
Asset turnover: 0.12090977249520507
ROE archetype: Standard Business
Treasury beta 1y: -0.003488662497273145 (R-squared: 0.0008266003009640336)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): 4.026663578694583 (pretax: 5.097042504676687)
Incremental ROIC 3y (%): -4.17054225966935 (pretax: -5.2791674173029755)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B , ROIC 54.385964912280706, revenue growth 1y 24.561403508771928, 6m momentum 77.19298245614034
Sector percentiles: P/E , 6m momentum 72.4269819193324
Industry median P/E: 9.793103448275863; industry median ROIC: 5.393231631533984
Sector median P/E: 0.5734625271900335; sector median ROIC: 5.974200780604355
WACC: 0.07860280454293322
Base cash flow: -24926000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for COAG (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 47.31
Market cap: 2209633024 (USD: 2209633024)
Debt to equity: 0.0066
Current ratio: 12.85
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 2.5372875554922585 (Grey Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 64.49930458970793, 3m , 6m , 12m , composite  ()
Lynch category: Turnaround (confidence: Medium)
Screener: long score 3, short score 8, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.005654520763674126
FCF conversion rate: 0.956318596553092
Beneish M-score: -0.03407461015986285 (Strong Manipulation Signal)
Asset turnover: 0
ROE archetype: Standard Business
Treasury beta 1y: -0.4283926615817201 (R-squared: 0.08168106067966388)
Insider 90-day net shares: 2970541 (net value USD: 75094670.00)
Capital allocation category: Standard Allocator
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.052851
Base cash flow: -63625000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for COTY.PA (Consumer Defensive — Household & Personal Products, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 2.1477272727272725
Market cap: 1664081536 (USD: 1664081536)
P/B ratio: 0.5202200929006897
Debt to equity: 0.9781
Current ratio: 0.82
Interest coverage ratio: -0.28486646884273
Buffett classification: The Gruesome
Analyst consensus upside (%): 6.333333333333336
Rule of 40 score: -43.58667874349247
Altman Z-score: -0.5639853609634788 (Distress Zone)
Piotroski F-score: 3 (Weak)
Magic formula: return on capital % 136.08617594254937, earnings yield % 10.121547323127025, rank 126
Dividend yield (%): 0.1983075906203673
Buyback yield (%): 0
Debt paydown yield (%): -9.687025335758548
Total shareholder yield (%): -9.488717745138182 (Minimal or Negative)
Momentum (%): 1m 11.221590909090905, 3m -2.7870813397129264, 6m -30.036157024793397, 12m -57.54492600422834, composite -31.55054216534066 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 1, short score 9, recommendation: Short
Revenue growth 1y (%): -1.3470864444615538
Revenue deceleration: no
Accrual ratio: -0.01473763259175819
FCF conversion rate: 0.6130145427655903
Beneish M-score: -2.5446560243229013 (Likely Safe)
ROE (%): -10.89654061022776
Net margin (%): -31.655742821473158
Asset turnover: 0.12030413967896367
Equity multiplier (leverage): 2.8612483884830255
ROE archetype: Low Return
FCF z-score: 5.681683062473975
Treasury beta 1y: 0.01979089401457505 (R-squared: 0.00010124977680927189)
Insider 90-day net shares: 88000 (net value USD: 213537.00)
ROIC (%): 5.276810554275715 (pretax: 6.679507030728754)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E , P/B 14.3646408839779, ROIC 56.9060773480663, revenue growth 1y 29.83425414364641, 6m momentum 70.71823204419888
Sector percentiles: P/E , 6m momentum 70.38377986965966
Industry median P/E: 1.0386203196660713; industry median ROIC: 10.090126010498068
Sector median P/E: 1.0302878025850322; sector median ROIC: 7.163828537874342
WACC: 0.07125192374275502
Base cash flow: -145200000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CPAY (Technology — Software - Infrastructure, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 370.58
Market cap: 24221818880 (USD: 24221818880)
P/E ratio: 17.41412327947337
P/B ratio: 4.922907975668189
Debt to equity: 2.7133999999999996
Current ratio: 0.98
Interest coverage ratio: 4.675222524977293
Return on net tangible assets (%): -6.060106322748481
Buffett classification: The Great
Analyst consensus upside (%): 35.791607959036384
Rule of 40 score: -9.699984246853587
Altman Z-score: 1.2896865609755581 (Distress Zone)
Piotroski F-score: 4 (Weak)
Magic formula: return on capital % 442.3094108750945, earnings yield % 1.583567138644341, rank 216
Dividend yield (%): 0
Buyback yield (%): 3.2448884367184236
Debt paydown yield (%): -1.4819407319422577
Total shareholder yield (%): 1.762947704776166 (Low Return)
Momentum (%): 1m 7.645384302562015, 3m 18.43021955194783, 6m 15.618370148508676, 12m 11.101783840503664, composite 12.419834202355732 (Flat)
Lynch category: Fast Grower (confidence: High)
Screener: long score 2, short score 12, recommendation: Short
Revenue growth 1y (%): 25.388125492832113
Net income growth 1y (%): 45.03905689390055
Revenue deceleration: no
Accrual ratio: 0.017388376465024304
FCF conversion rate: -0.3045172088184239
Beneish M-score: -2.2080713189267165 (Likely Safe)
ROE (%): 8.742120014893393
Net margin (%): 28.05056673859445
Asset turnover: 0.04751903159661918
Equity multiplier (leverage): 6.558545603106407
ROE archetype: Standard Business
P/E z-score: 4.725448164090262
FCF z-score: 4.725448164090272
Treasury beta 1y: -8.914199943100685e-05 (R-squared: 1.0882580736153754e-06)
Insider 90-day net shares: -93237 (net value USD: -32907442.00)
ROIC (%): 11.4795475069819 (pretax: 16.509921489677065)
Incremental ROIC 3y (%): 7.472163259284343 (pretax: 13.731994978041845)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 36.425339366515836, P/B 52.03619909502263, ROIC 28.28054298642534, revenue growth 1y 20.361990950226243, 6m momentum 14.705882352941178
Sector percentiles: P/E 38.83883883883884, 6m momentum 20.887554220887555
Industry median P/E: 5.36821412369575; industry median ROIC: 3.7232145830700096
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.07263951434626843
Base cash flow: 1264495000
DCF price per share: base 626.1781932563981, conservative 354.05783430447866, aggressive 1072.8022039181396
Financial scorecard for CRBU (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 1.57
Market cap: 155713504 (USD: 155713504)
P/B ratio: 1.8471553304318846
Debt to equity: 0.2641
Current ratio: 6.22
Return on net tangible assets (%): -24.023211590111547
Buffett classification: The Gruesome
Analyst consensus upside (%): 531.578947368421
Rule of 40 score: -1266.253384691619
Altman Z-score: -3.590708088482146 (Distress Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.18045962153674225
Total shareholder yield (%): 0.18045962153674225 (Low Return)
Momentum (%): 1m -5.421686746987944, 3m -26.291079812206565, 6m 2.6143790849673225, 12m -33.755274261603375, composite -17.878168878137416 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): 1.8699532511687211
Revenue deceleration: no
Accrual ratio: 0.012152975814283292
FCF conversion rate: 1.0785728523021727
Beneish M-score: -2.775678385641785 (Likely Safe)
ROE (%): -22.378040349163445
Net margin (%): -1046.5164789319983
Asset turnover: 0.014779646386015755
Equity multiplier (leverage): 1.4468114526323301
ROE archetype: Low Return
Treasury beta 1y: -0.002118938271986888 (R-squared: 0.00014590156872310156)
Insider 90-day net shares: -24317 (net value USD: -47473.00)
ROIC (%): -1069.3029218843171 (pretax: -1353.5480023852117)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 21.660649819494584, ROIC 42.32851985559567, revenue growth 1y 16.967509025270758, 6m momentum 25.902527075812277
Sector percentiles: P/E , 6m momentum 25.608882521489974
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.15
Base cash flow: -145839000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CRDL.TO (Healthcare — Drug Manufacturers - Specialty & Generic, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 1.1843971631205674
Market cap: 192504640 (USD: 138492546.76258993)
P/B ratio: 9.001437349155415
Debt to equity: 0.0048
Current ratio: 4.39
Return on net tangible assets (%): -44.78506137901415
Buffett classification: The Gruesome
Analyst consensus upside (%): 341.2698412698413
Rule of 40 score: 0
Altman Z-score: 5.956837127189212 (Safe Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.005686851264854967
Total shareholder yield (%): 0.005686851264854967 (Low Return)
Momentum (%): 1m 12.875434337664798, 3m -14.146872302900654, 6m 15.103386275097384, 12m -16.105200945626468, composite -8.239456218970412 (Strong Downtrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 8, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.1175110455399879
FCF conversion rate: 0.6992793607373382
Beneish M-score: -2.774026761513929 (Likely Safe)
ROE (%): -51.10096849580476
Asset turnover: 0
Equity multiplier (leverage): 1.3077167207886227
ROE archetype: Low Return
Treasury beta 1y: -0.001586364555967472 (R-squared: 0.00010411929339907936)
Insider 90-day net shares: 150000 (net value USD: 150000.00)
Incremental ROIC 3y (%): 150.867628952052 (pretax: 190.9716822177873)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 73.90029325513197, ROIC , revenue growth 1y , 6m momentum 21.994134897360702
Sector percentiles: P/E , 6m momentum 17.012893982808023
Industry median P/E: 0.8814835040505258; industry median ROIC: 5.747543732928968
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.07493659965713574
Base cash flow: -24628740.875912406
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CREO.L (Healthcare — Medical Devices, United Kingdom)
Report date: 2025-12-31 (annual)
Stock price: 0.0018666666666666669
Market cap: 66191156 (USD: 89447508.1081081)
P/E ratio: 0.09166163150943397
P/B ratio: 0.00971613294
Debt to equity: 0.08199999999999999
Current ratio: 4.65
Interest coverage ratio: -65
Return on net tangible assets (%): 12.93634496919918
Buffett classification: The Gruesome
Analyst consensus upside (%): 4069900
Rule of 40 score: -294.50450450450455
Piotroski F-score: 5 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0.15107758504776683
Debt paydown yield (%): -0.0453232755143301
Total shareholder yield (%): 0.10575430953343673 (Low Return)
Momentum (%): 1m 1.3333333333333344, 3m 15.111111111111128, 6m 15.111111111111128, 12m -1.3333333333333328, composite 9.196881091617945 (Moderate Downtrend)
Lynch category: Asset Play (confidence: High)
Screener: long score 3, short score 6, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.543436153359016 (Likely Safe)
Equity multiplier (leverage): 1.1531152686168258
ROE archetype: Standard Business
P/E z-score: 1.6291983476775855
Treasury beta 1y: 0.0001961996375811395 (R-squared: 1.4916983256457676e-06)
Insider 90-day net shares: 12500 (net value USD: 2324.00)
ROIC (%): -36.94244604316546 (pretax: -46.762589928057544)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E 2.0771513353115725, P/B 0.2967359050445104, ROIC 45.6973293768546, revenue growth 1y , 6m momentum 10.385756676557865
Sector percentiles: P/E 3.044412607449857, 6m momentum 16.977077363896846
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.09849410243179271
Base cash flow: 8513513.513513513
DCF price per share: base 0.002566440070974664, conservative 0.0023314016672761075, aggressive 0.0028427218468200406
Financial scorecard for CSTL (Healthcare — Diagnostics & Research, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 24.68
Market cap: 748694848 (USD: 748694848)
P/B ratio: 1.6137288728609325
Debt to equity: 0.0796
Current ratio: 6.75
Interest coverage ratio: -137.36567164179104
Return on net tangible assets (%): -6.328745375189867
Buffett classification: The Gruesome
Analyst consensus upside (%): 74.25661914460285
Rule of 40 score: -56.84040138341008
Altman Z-score: 5.2451586660555085 (Safe Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.025243929553526192
Total shareholder yield (%): 0.025243929553526192 (Low Return)
Momentum (%): 1m 11.57323688969258, 3m 0.8994276369582946, 6m -41.5719696969697, 12m 50.213024954351795, composite -2.0135903032255484 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 9, recommendation: Short
Revenue growth 1y (%): -4.8972587170977855
Revenue deceleration: no
Accrual ratio: 0.03562268224840882
FCF conversion rate: 2.381490152871505
Beneish M-score: -2.414084069795832 (Likely Safe)
ROE (%): -3.1153429891374884
Net margin (%): -17.354413891179387
Asset turnover: 0.14858291435871804
Equity multiplier (leverage): 1.2081672099531369
ROE archetype: Low Return
FCF z-score: 3.180934118229706
Treasury beta 1y: 0.0008647151968576428 (R-squared: 3.483448137081188e-05)
Insider 90-day net shares: -63369 (net value USD: -1420047.00)
ROIC (%): -16.237630892880293 (pretax: -20.553963155544672)
Incremental ROIC 3y (%): 70.24483037751122 (pretax: 88.91750680697623)
Capital allocation category: Turnaround Compounder
Industry percentiles: P/E , P/B 25, ROIC 58.08823529411765, revenue growth 1y 47.794117647058826, 6m momentum 77.20588235294117
Sector percentiles: P/E , 6m momentum 66.22492836676219
Industry median P/E: 21.640734060420083; industry median ROIC: 2.9089897435686405
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.09886445418699723
Base cash flow: -19363000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CSTR.V (Financial Services — Capital Markets, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 0
Market cap: 2329486 (USD: 1675889.2086330936)
P/B ratio: 0
Debt to equity: 1.0729
Current ratio: 1.02
Interest coverage ratio: -10.452441836093062
Return on net tangible assets (%): -20.401692049163213
Buffett classification: The Gruesome
Rule of 40 score: -898.6523321574753
Altman Z-score: -21.900404993868506 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 10.282130719842817
Total shareholder yield (%): 10.282130719842817 (High Return)
Momentum (%): 1m , 3m , 6m -100, 12m -100, composite -100 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 0, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): -72.50541450847558
Revenue deceleration: no
Revenue growth consistency score: 108.87893591252407
Accrual ratio: -0.08008074134405956
FCF conversion rate: 0.40467535627918294
Beneish M-score: -2.719485090142906 (Likely Safe)
ROE (%): -38.45540534918811
Net margin (%): -2110.637614862967
Asset turnover: 0.006373244069782165
Equity multiplier (leverage): 2.8587960231643468
ROE archetype: Low Return
Treasury beta 1y: -7.692227117011418 (R-squared: 0.03266087333937944)
Insider 90-day net shares: 84600000 (net value USD: 930600.00)
ROIC (%): -80.79954825190637 (pretax: -102.27790917962831)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E , P/B 73.07692307692307, ROIC 57.692307692307686, revenue growth 1y 56.59340659340659, 6m momentum 85.16483516483517
Sector percentiles: P/E , 6m momentum 70.87428867046043
Industry median P/E: 0.9254498714652956; industry median ROIC: 1.51204420306575
Sector median P/E: 9.286368843069873; sector median ROIC: 1.3915857507207385
WACC: 0.1217611759967781
Base cash flow: -1945706.5693430654
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CVGI (Consumer Cyclical — Auto Parts, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 4.62
Market cap: 156820640 (USD: 156820640)
P/E ratio: 32.08109097560976
P/B ratio: 0.883657863621095
Debt to equity: 1.0969
Current ratio: 2.13
Interest coverage ratio: 0.18461538461538463
Return on net tangible assets (%): -6.747165204598277
Buffett classification: The Gruesome
Analyst consensus upside (%): 119.94134897360702
Rule of 40 score: 7.814330617511148
Altman Z-score: 0.857709282792852 (Distress Zone)
Piotroski F-score: 6 (Neutral)
Magic formula: return on capital % 0.36092810083070753, earnings yield % 0.2793841462830556, rank 2724
Dividend yield (%): 0
Buyback yield (%): 0.36666091912391124
Debt paydown yield (%): 26.814710104486245
Total shareholder yield (%): 27.181371023610158 (High Return)
Momentum (%): 1m 0.21691973969630773, 3m 8.70588235294118, 6m 185.18518518518516, 12m 145.74468085106383, composite 113.03461116519107 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 1, short score 6, recommendation: Neutral
Revenue growth 1y (%): 1.0012073382608344
Revenue deceleration: no
Accrual ratio: 0.012722206541889904
FCF conversion rate: -4.671840354767184
Beneish M-score: -1.727670144200943 (Possible Manipulation)
ROE (%): 0.6824415063647884
Net margin (%): 0.5259628560599434
Asset turnover: 0.4264649747657172
Equity multiplier (leverage): 3.0424747961943672
ROE archetype: Low Return
FCF z-score: 3.5248094713004425
Treasury beta 1y: -0.004178174141348938 (R-squared: 0.00045174671499590124)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -0.2122220993705901 (pretax: -0.26863556882353185)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 69.6969696969697, P/B 38.01652892561984, ROIC 82.92011019283747, revenue growth 1y 41.8732782369146, 6m momentum 0.27548209366391185
Sector percentiles: P/E 58.796940194714885, 6m momentum 0.6606397774687065
Industry median P/E: 0.2842479295922772; industry median ROIC: 7.591641841963527
Sector median P/E: 0.5734625271900335; sector median ROIC: 5.974200780604355
WACC: 0.08512331587113262
Base cash flow: -18650000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CYL.AX (Basic Materials — Gold, Australia)
Report date: 2024-06-30 (annual)
Stock price: 3.9097222222222223
Market cap: 1471130880 (USD: 980753920)
P/E ratio: 1.8373983739837398
P/B ratio: 1.5119791387079593
Debt to equity: 0.0282
Current ratio: 2.19
Interest coverage ratio: 6.6532339993227225
Return on net tangible assets (%): 16.425883750866422
Buffett classification: The Good
Analyst consensus upside (%): 1480.9734513274336
Rule of 40 score: 411.0484742051396
Altman Z-score: 7.286598985340241 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Magic formula: return on capital % 16.11539234463497, earnings yield % 2.091820714617317, rank 2830
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.03997240256529015
Total shareholder yield (%): 0.03997240256529015 (Low Return)
Momentum (%): 1m 1.2338789682539781, 3m -12.840587402689312, 6m -39.59582598471487, 12m 19.75011268875368, composite -11.381954307423877 (Moderate Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 9, short score 0, recommendation: Long
Revenue growth 1y (%): 399.0732932983027
Revenue CAGR 3y (%): 114.43041201878046
Revenue deceleration: no
Revenue growth consistency score: 208.29264469871748
Accrual ratio: -0.04406444534144934
FCF conversion rate: 1.611469564479158
Beneish M-score: 0.5762725413808466 (Strong Manipulation Signal)
ROE (%): 12.875917767908525
Net margin (%): 7.431217548751791
Asset turnover: 0.9697359302654787
Equity multiplier (leverage): 1.7867538712456001
ROE archetype: Standard Business
P/E z-score: 4.35459949119438
FCF z-score: 3.532830860481944
Treasury beta 1y: 0.004482162300796324 (R-squared: 0.000718260171720724)
Insider 90-day net shares: -2000000 (net value USD: -11576425.00)
ROIC (%): 19.304453667370087 (pretax: 20.76224393285321)
Incremental ROIC 3y (%): 21.545918256374296 (pretax: 23.04887504209474)
Capital allocation category: High-Efficiency Compounder
Industry percentiles: P/E 4.2492917847025495, P/B 15.722379603399434, ROIC 9.34844192634561, revenue growth 1y 0.424929178470255, 6m momentum 56.09065155807366
Sector percentiles: P/E 19.017212659633536, 6m momentum 63.35369239311493
Industry median P/E: 8.322060300477567; industry median ROIC: -7.9824265928961236
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.11585565586605971
Base cash flow: 22118000
DCF price per share: base 0.30896693113828294, conservative 0.18405483228531258, aggressive 0.5248548732966456
Financial scorecard for DNLI (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 23.11
Market cap: 3667782400 (USD: 3667782400)
P/B ratio: 3.290393619681718
Debt to equity: 0.0432
Current ratio: 9.29
Return on net tangible assets (%): -14.285168599412648
Buffett classification: The Gruesome
Analyst consensus upside (%): 78.69791666666669
Rule of 40 score: 0
Altman Z-score: 4.570289751973468 (Safe Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.06044524342556418
Total shareholder yield (%): 0.06044524342556418 (Low Return)
Momentum (%): 1m -6.889605157131349, 3m 16.3059889280322, 6m 14.123456790123454, 12m 61.4954577218728, composite 34.624862991539885 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 8, recommendation: Short
Revenue deceleration: no
Accrual ratio: 0.004332863103343721
FCF conversion rate: 1.0406626857770132
Beneish M-score: -2.977912193466996 (Likely Safe)
ROE (%): -13.242921263865053
Asset turnover: 0
Equity multiplier (leverage): 1.2428104310674126
ROE archetype: Low Return
Treasury beta 1y: -0.006469083662418917 (R-squared: 0.002474736221479199)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -240.21297867913577 (pretax: -304.0670616191592)
Incremental ROIC 3y (%): -40.74583546637249 (pretax: -51.577006919458846)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 35.46931407942238, ROIC 32.49097472924188, revenue growth 1y , 6m momentum 18.592057761732853
Sector percentiles: P/E , 6m momentum 17.693409742120345
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.09905192058538538
Base cash flow: -507230000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for DNO.V (Basic Materials — Gold, Canada)
Report date: 2026-05-31 (quarterly)
Stock price: 0.3049645390070922
Market cap: 14786398 (USD: 10714781.159420291)
Current ratio: 1.44
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 73.21985815602835, 3m 248.1678486997636, 6m 250.70921985815602, 12m 314.75177304964535, composite 212.77122942540984 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 0, short score 2, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.48 (Likely Safe)
ROE archetype: Standard Business
Treasury beta 1y: -0.003255830370432481 (R-squared: 0.00010911586357769689)
Insider 90-day net shares: 721000 (net value USD: 54968.00)
ROIC (%): -7.447794247376081 (pretax: -9.42758765490643)
Incremental ROIC 3y (%): 19.460037437198974 (pretax: 24.632958781264524)
Capital allocation category: Turnaround Compounder
Industry percentiles: P/E , P/B , ROIC 29.036827195467424, revenue growth 1y , 6m momentum 0.141643059490085
Sector percentiles: P/E , 6m momentum 0.44419766796224325
Industry median P/E: 8.322060300477567; industry median ROIC: -7.9824265928961236
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.05
Base cash flow: -201362.14285714287
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for DO2.DE (Consumer Cyclical — Footwear & Accessories, United States)
Report date: 2026-06-30 (quarterly)
Stock price: 95.06818181818181
Market cap: 11618781184 (USD: 11618781184)
P/E ratio: 16.57472786113563
Debt to equity: 0.2052
Current ratio: 2.75
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Magic formula: return on capital % 46.44347325305068, earnings yield % 12.100449528802084, rank 218
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -11, 3m -14.227196429252661, 6m -4.931818181818187, 12m -74.81833762996118, composite -30.288337316035296 (Strong Downtrend)
Lynch category:  (confidence: Medium)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.48 (Likely Safe)
ROE archetype: Standard Business
P/E z-score: 3.939802223815353
FCF z-score: 3.939802223815354
Treasury beta 1y: 0.02978018743691282 (R-squared: 0.00013410701193388995)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): 100.77474943139836 (pretax: 130.52141263333482)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E 52.4390243902439, P/B , ROIC 0, revenue growth 1y , 6m momentum 47.5609756097561
Sector percentiles: P/E 51.495132127955486, 6m momentum 43.35883171070932
Industry median P/E: 0.9799484309852973; industry median ROIC: 7.280704973433667
Sector median P/E: 0.5734625271900335; sector median ROIC: 5.974200780604355
WACC: 0.10834277653303617
Base cash flow: 1015221000
DCF price per share: base 226.25732512200014, conservative 133.89671905158934, aggressive 390.6935811447882
Financial scorecard for DTCX (Financial Services — Financial Data & Stock Exchanges, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 1.87
Market cap: 72693680 (USD: 72693680)
P/B ratio: 1.0559306579268155
Debt to equity: 0
Current ratio: 229.91
Return on net tangible assets (%): -3.6267974972731105
Buffett classification: The Gruesome
Rule of 40 score: 1064.0870447590312
Altman Z-score: 168.33211911452221 (Safe Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -11.792452830188678, 3m -17.982456140350866, 6m -17.982456140350866, 12m -86.7844522968198, composite -40.327526708408236 (Strong Downtrend)
Lynch category: Turnaround (confidence: Medium)
Screener: long score 4, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.03683364124987622
FCF conversion rate: 0.5245220554229907
Beneish M-score: 10.290115517136249 (Strong Manipulation Signal)
ROE (%): -7.772084785809802
Net margin (%): -282.29095157506765
Asset turnover: 0.027442098543166392
Equity multiplier (leverage): 1.0032825356487147
ROE archetype: Low Return
Treasury beta 1y: 0.009589019470380633 (R-squared: 0.0011825105691398872)
Insider 90-day net shares: 50000 (net value USD: 154500.00)
ROIC (%): -22.890685941909776 (pretax: -28.97555182520225)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 4.651162790697675, ROIC 67.44186046511628, revenue growth 1y , 6m momentum 69.76744186046511
Sector percentiles: P/E , 6m momentum 59.15675116399379
Industry median P/E: 19.132963988919666; industry median ROIC: 11.257628306763747
Sector median P/E: 9.286368843069873; sector median ROIC: 1.3915857507207385
WACC: 0.1019
Base cash flow: -30507790
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for DTI (Energy — Oil & Gas Equipment & Services, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 2.31
Market cap: 81171312 (USD: 81171312)
P/B ratio: 1.2633769566480948
Debt to equity: 0.637
Current ratio: 2.15
Interest coverage ratio: -0.3020730503455084
Buffett classification: The Gruesome
Analyst consensus upside (%): 3.926096997690529
Rule of 40 score: -33.00185207455674
Altman Z-score: 0.7726429108498448 (Distress Zone)
Piotroski F-score: 2 (Weak)
Magic formula: return on capital % 6.687195200570349, earnings yield % 5.6860281654506375, rank 3401
Dividend yield (%): 0
Buyback yield (%): 0.8697654166289686
Debt paydown yield (%): -6.250976946140774
Total shareholder yield (%): -5.3812115295118055 (Minimal or Negative)
Momentum (%): 1m 7.441860465116286, 3m -30.421686746987948, 6m -39.84374999999999, 12m 1.3157894736842215, composite -25.322397044317615 (Moderate Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 1, short score 9, recommendation: Short
Revenue growth 1y (%): -11.476212686567166
Revenue deceleration: no
Accrual ratio: 0.04354179300529671
FCF conversion rate: 7.325747724317295
Beneish M-score: -2.3475605843594347 (Likely Safe)
ROE (%): -1.2642516008647546
Net margin (%): -4.051740035301246
Asset turnover: 0.1698841526043846
Equity multiplier (leverage): 1.8367035749221146
ROE archetype: Low Return
Treasury beta 1y: 0.0029678457986290385 (R-squared: 0.0002688921171867061)
Insider 90-day net shares: -10415 (net value USD: -34411.00)
ROIC (%): 3.649305810237334 (pretax: 4.619374443338398)
Incremental ROIC 3y (%): -13.598982657797826 (pretax: -15.39583956899132)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 35.60606060606061, ROIC 58.333333333333336, revenue growth 1y 54.54545454545454, 6m momentum 81.81818181818183
Sector percentiles: P/E , 6m momentum 72.05153617443013
Industry median P/E: 14.518489818761033; industry median ROIC: 5.879956809181115
Sector median P/E: 11.598358576086895; sector median ROIC: 4.629877910100043
WACC: 0.05
Base cash flow: 17574000
DCF price per share: base 28.92387078666925, conservative 17.586349430114574, aggressive 48.99587924671646
Financial scorecard for EBGNG.NS (Technology — Computer Hardware, India)
Report date: 2026-03-31 (annual)
Stock price: 5.9078241123038815
Market cap: 65254490112 (USD: 691548220.7715133)
P/E ratio: 2.3963814334043523
P/B ratio: 5.262499001244642
Debt to equity: 0.5854
Current ratio: 2.51
Interest coverage ratio: 4.381537373261024
Return on net tangible assets (%): 15.771957328434866
Buffett classification: The Great
Analyst consensus upside (%): 15636.091464280642
Rule of 40 score: 8.893357318871708
Altman Z-score: 9.261816007648678 (Safe Zone)
Piotroski F-score: 2 (Weak)
Magic formula: return on capital % 7.7814428078387925, earnings yield % 0.009302694448692916, rank 2011
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 5.696747934038244, 3m 44.693644036153096, 6m 114.65094274704104, 12m , composite 79.67229339159707 (Strong Uptrend)
Lynch category: Fast Grower (confidence: Medium)
Screener: long score 8, short score 3, recommendation: Neutral
Revenue growth 1y (%): 70.55291880974531
Net income growth 1y (%): 100.89131443283219
Revenue deceleration: no
Beneish M-score: 0.4169738925777395 (Strong Manipulation Signal)
ROE (%): 5.550660908981961
Net margin (%): 6.467839577690649
Asset turnover: 0.5196685438865949
Equity multiplier (leverage): 1.6514256590981822
ROE archetype: Standard Business
P/E z-score: 2.388945287911582
Treasury beta 1y: -5.5665489166247815e-05 (R-squared: 2.3382484439467358e-07)
Insider 90-day net shares: -4233203 (net value USD: 1348427.00)
ROIC (%): 15.456746728293954 (pretax: 17.297984146857996)
Incremental ROIC 3y (%): 15.089034061590636 (pretax: 17.04381264560622)
Capital allocation category: High-Efficiency Compounder
Industry percentiles: P/E 20.66115702479339, P/B 55.371900826446286, ROIC 25.6198347107438, revenue growth 1y 11.570247933884298, 6m momentum 8.264462809917356
Sector percentiles: P/E 29.129129129129126, 6m momentum 3.0363697030363697
Industry median P/E: 8.88268187417684; industry median ROIC: 2.6060646680961477
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.10188987107654285
Base cash flow: 12666172.106824927
DCF price per share: base 0.022025176016476668, conservative 0.011915205581506393, aggressive 0.03986571076863944
Financial scorecard for EMA.AX (Basic Materials — Other Industrial Metals & Mining, Australia)
Report date: 2025-06-30 (annual)
Stock price: 0.02777777777777778
Market cap: 6225157 (USD: 4068730.065359477)
Debt to equity: 0.0018
Current ratio: 2.16
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 0.6944444444444402, 3m -22.222222222222225, 6m -32.407407407407405, 12m -47.56944444444444, composite -34.18688803746275 (Strong Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.48 (Likely Safe)
ROE archetype: Standard Business
Treasury beta 1y: 0.002974851963000284 (R-squared: 0.0001368263252593385)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y , 6m momentum 44.12989175686928
Sector percentiles: P/E , 6m momentum 56.19100499722376
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.11400000000000002
Base cash flow: 0
DCF price per share: base 0, conservative 0, aggressive 0